Court Blocks Mifepristone Mail Distribution

A federal appeals court, the United States — United States Court of Appeals for the Third Circuit, has restricted access to Mifepristone, a widely used abortion pill, by blocking its distribution via mail. The unanimous ruling requires the drug to be dispensed only in person at clinics, overturning previous regulations set by the United States — Food and Drug Administration. This decision stems from a lawsuit initiated by United States — Louisiana's attorney general, Liz Murrill, who argued that the United States — Food and Drug Administration's mail-order allowances undermined the state's abortion ban. The ruling, which is expected to be appealed to the United States — Supreme Court of the United States, marks a significant shift in abortion policy since the overturning of Roe v. Wade in 2022. Critics like Julia Kaye of the American Civil Liberties Union warn of negative impacts on patient access, especially for vulnerable communities. Manufacturers like Abbott Laboratories and GenBioPro have expressed concern, with Abbott Laboratories seeking an emergency appeal to the United States — Supreme Court of the United States. The ruling also highlights the differing stances of past administrations, with Donald Trump's administration initiating a review of Mifepristone's safety and Joe Biden's administration easing restrictions.